Worth reading
31Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Who is moving to which position
Resolved 27 July 2026Incoming appointee
1 itemScheduled Appointment Date27 July 2026 (assuming office on the same day)
Kurihara Nobukazu (栗原 伸和)
Previous positionDAIICHI SANKYO COMPANY,LIMITED, General Manager of the Business Development Department and Head of the Global Alliance Management function, among other positions
New positionChief Business Development Officer (CBDO)
Reason for change
To further strengthen the business development function and make a significant contribution to promoting out-licensing activities and strategic alliances aimed at maximizing the value of the drug discovery pipeline.
Details of organizational changes
Establishment of the Chief Business Development Officer (CBDO) position
| Item | Details |
|---|---|
| Resolution date | 27 July 2026 |
| Scheduled Appointment Date | 27 July 2026 (assuming office on the same day) |
| Name of appointee | Kurihara Nobukazu (栗原 伸和) |
| Appointee's new position | Chief Business Development Officer (CBDO) |
| Appointee's previous position | DAIICHI SANKYO COMPANY,LIMITED, General Manager of the Business Development Department and Head of the Global Alliance Management function, among other positions |
| Reason for change | To further strengthen the business development function and make a significant contribution to promoting out-licensing activities and strategic alliances aimed at maximizing the value of the drug discovery pipeline. |
| Details of organizational changes | Establishment of the Chief Business Development Officer (CBDO) position |
Items this document does not state (14)
Date of departureAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReasons for appointmentNumber of directors after the changeFiling as an independent officerChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To further strengthen the business development function and promote out-licensing activities and strategic alliances aimed at maximizing the value of the drug discovery pipeline.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.